Background
==========

Medulloblastoma (MBL), an embryonal neuroectodermal tumor of the cerebellum, is the most common type of malignant brain tumor in children. Although recent advances in MBL therapy have led to a dramatic increase in survival rate, the mortality rate is currently approximately 20--40% \[[@B1]\]. Moreover, MBL survivors are often affected by treatment-related side effects such as growth hormone deficiency, gonadal alterations, hypo- or hyperthyroidism, and long-term cognitive, neuropsychological and academic impairments, etc. New approaches are thus needed to improve the survival rate and to reduce the negative side effects of MBL treatment \[[@B2]\].

The induced differentiation of tumor cells has become a promising strategy in modern antineoplastic therapy. Retinoids, which are derivatives of vitamin A, are the most frequently used group of cell differentiation inducers. The regulation of relevant cell signaling pathways via retinoids is based on the activation of two groups of nuclear receptors, RAR and RXR \[[@B3],[@B4]\]. These activated receptors can influence the transcription either directly by binding to the DNA or indirectly by interacting with other transcription factors \[[@B5],[@B6]\].

In general, retinoids play an important role in cell proliferation and differentiation, and their efficacy in the treatment of various types of tumor cells has been described both *in vivo* and *in vitro*\[[@B7]-[@B11]\]. However, the toxicity of and intrinsic or acquired resistance to retinoids substantially limit their use in clinical protocols \[[@B12]\].

Therefore, special attention has been paid to treating cancer cells with a combination of retinoids and other compounds that may enhance or prolong their antineoplastic effects. The enhancing effects of these modulators were described in several clinical trials focused on the treatment of leukemia \[[@B13]-[@B16]\]; they were also demonstrated under *in vitro* conditions using tumor cells of a neurogenic origin \[[@B17]-[@B20]\].

To date, many studies on various cancer cell lines have reported the additive or synergistic effects of combined treatment with retinoids and inhibitors of lipoxygenases (LOX) \[[@B21]-[@B24]\] or cyclooxygenases (COX) \[[@B25]-[@B27]\]. The molecular mechanisms of this modulation remain unknown, but the published data suggest the inhibition of the retinoid degradation pathways \[[@B28]\] or the cooperation of compounds that are utilized in cell signaling inhibition (through the PI3K/Akt pathway) or the induction of the mitochondrial apoptotic pathway \[[@B25]\].

Our previous studies were also focused on how to enhance the differentiation effect of all-*trans* retinoic acid (ATRA) through its combination with LOX/COX inhibitors in neuroblastoma cell lines \[[@B20],[@B29]\]. In these experiments, we used caffeic acid (CA) as an inhibitor of 5-LOX and celecoxib (CX) as an inhibitor of COX-2. Our results clearly confirmed that the ATRA-induced differentiation of neuroblastoma cells can be enhanced via the combined application of these inhibitors \[[@B20],[@B29]\]. Furthermore, data from the expression profiling of the treated cells showed an increase in the expression of the genes involved in the process of retinoid-induced neuronal differentiation, especially in cytoskeleton remodeling after combined treatment \[[@B20]\].

To verify these findings, we used a different type of neurogenic tumor cells, i.e. established medulloblastoma cell lines but the same experimental design for the treatment of these cells. Our new data from the gene expression profiling of medulloblastoma cells also demonstrated the capability of CA or CX to enhance the cell differentiation induced via ATRA.

Methods
=======

Cell lines and cell culture
---------------------------

Daoy (ATCC HTB-186™) and D283 Med (ATCC HTB-185™) medulloblastoma cell lines were used in this study. These cell lines were chosen according their different origin (primary tumor vs. metastatic site) and their different biological features as described by supplier in the documentation to cover known heterogeneity in this disease. Both of these cell lines are widely used in medulloblastoma research. These cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM)/Ham's F-12 medium mixture (1:1) supplemented with 20% fetal calf serum, 1% non-essential amino acids, 2 mM L-glutamine, 100 IU.ml^-1^ penicillin, and 100 mg.ml^-1^ streptomycin (all purchased from PAA Laboratories, Linz, Austria). Cell culture was performed under standard conditions at 37°C in a humidified atmosphere containing 5% CO~2~. Both of these cell lines were subcultured 1--2 times weekly. The Research Ethics Committee of the University Hospital Brno approved the study protocol.

Chemicals
---------

ATRA (Sigma-Aldrich, St. Louis, MO, USA), CA (Sigma), and CX (LKT Laboratories, St. Paul, MN, USA) were prepared as stock solutions at concentrations of 100 mM in dimethyl sulfoxide (DMSO) (Sigma). For experiments, these stock solutions were diluted in fresh cell culture medium to obtain final concentrations as follow: 0.05 and 0.1 μM of ATRA for the treatment of D283 Med cells, 1 and 10 μM of ATRA for the treatment of Daoy cells, 13 and 52 μM of CA, as well as 10 and 50 μM of CX for the treatment of both cell lines.

Experimental design
-------------------

The experimental design was the same as that in our previous studies \[[@B20],[@B29]\]: the cell populations were treated with ATRA alone or with ATRA and an inhibitor (CA or CX) at the concentrations mentioned above. The concentrations of ATRA and inhibitors were chosen on the basis of previously published data, and they corresponded to the plasma levels obtained using these compounds therapeutically \[[@B23],[@B30]-[@B33]\]. However, lower concentrations of 0.05 and 0.1 μM ATRA were used for treating the D283 Med cells due to the predominant cytotoxic effect on the cell populations at higher concentrations \[[@B34]\]. In all experiments, the cells were seeded into Petri dishes or culture flasks 24 h prior to the treatment. Untreated cells were used as controls in all experiments.

Expression profiling
--------------------

The total RNA of the treated cell populations was isolated using the GenElute™ Mammalian Total RNA Miniprep Kit (Sigma), and its concentration and integrity were determined using a spectrophotometer. This isolation of RNA was performed at day 3 after treatment. The conversion of the experimental RNA into cDNA and its further transcription and biotin-UTP labeling was performed using TrueLabeling-AMP™ 2.0 cRNA (SABiosciences, Frederick, MD, USA). After purification with the SuperArray ArrayGrade cRNA Cleanup Kit, the labeled target cRNA was hybridized to Human Cancer OHS-802 Oligo GEArray membranes that profile 440 genes (both SABiosciences). The expression levels of each gene were detected via chemiluminescence using the alkaline phosphatase-conjugated streptavidin substrate. The membranes were then recorded using the MultiImage™ II Light Cabinet DE- 500 (Alpha Innotech, CA, USA). The image data were processed and analyzed using the GEArray Expression Analysis Suite software (SABiosciences) with background subtraction. All data were standardized as a ratio of the gene expression intensity to the mean expression intensity of the selected *HSP90AB1* housekeeping gene, which was chosen using the GeNorm \[[@B35]\] and NormFinder \[[@B36]\] software tools. Standardized spot intensity ratios (treated/control samples) were calculated and data filtering criteria were as follows: genes with ratio higher than 2 were rated as upregulated and genes with ratio lower than 0.5 were rated as downregulated. The expression of the specific gene was evaluated as changed if the same trend of change, i.e. upregulation or downregulation was detected at least in four experimental variants (of six in total) regardless the concentrations used for treatment. Cluster analyses were performed using the GEArray Expression Analysis Suite software according to the design of the experiments, i.e., separately for each cell line and inhibitor type. DAVID software tool \[[@B37]\] was used for primary detection of relevant pathways.

RT-PCR
------

The changes in the expression of the two selected candidate genes were evaluated using RT-PCR. The RNA was isolated as described above. A total of 0.25 μg RNA was then reverse transcribed using M-MLV reverse transcriptase (Top-Bio, Prague, Czech Republic) according to the manufacturer's protocol. RT-PCR was performed on 4 μl cDNA using Taq DNA polymerase 1.1 (Top-Bio) with human primers for the *CDKN1A* and *GDF15* candidate genes as well as the *HSP90AB1* housekeeping gene (Table [1](#T1){ref-type="table"}) in 20 μl of the reaction volume. The PCR reaction was performed with denaturation at 94°C for 4 min, annealing at 60°C for 30 s, and elongation at 72°C for 1 min (35 cycles for all primers) (Table [1](#T1){ref-type="table"}). A total of 10 μl of the PCR product was loaded on the 1% agarose gel and examined using electrophoresis. The optical density was stained and quantified using ImageJ software \[[@B38]\], and the data were normalized to *HSP90AB1* expression.

###### 

Sequences of primers used for RT-PCR

  **Gene**         **Primer sequence**                   **Product**
  ---------------- ------------------------------------- -------------
  ***CDKN1A***     F: 5′ TTA GCA GCG GAA CAA GGA GT 3′   225 bp
                   R: 5′ GCC GAG AGA AAA CAG TCC AG 3′    
  ***GDF15***      F: 5′ CTC CAG ATT CCG AGA GTT GC 3′   169 bp
                   R: 5′ AGA GAT ACG CAG GTG CAG GT 3′    
  ***HSP90AB1***   F: 5′ CGC ATG AAG GAG ACA CAG AA 3′   169 bp
                   R: 5′ TCC CAT CAA ATT CCT TGA GC 3′    

Results
=======

The present study was focused on a detailed analysis of Daoy and D283 Med medulloblastoma cells after the combined application of ATRA and LOX/COX inhibitors. CA as the specific inhibitor of 5-LOX and CX as the specific inhibitor of COX-2 were used in these experiments. The changes in the expression of cancer-related genes were evaluated using expression profiling. Furthermore, a detailed analysis of the expression of five candidate genes was performed using RT-PCR to verify the microarray results. We used the same experimental design as our previous studies on neuroblastoma cells \[[@B20],[@B29]\].In Daoy cells, changes in the expression of 80 cancer-related genes were detected after combined treatment with ATRA and inhibitors (Figure [1](#F1){ref-type="fig"}A). A total of 29 of these genes demonstrated changed expressions after combinations of ATRA and CA as well as of ATRA and CX. The expressions of another 29 genes were changed only after the combined treatment of ATRA and CA. A total of 22 different genes showed changes in expression after undergoing combined treatment with ATRA and CX (Figure [1](#F1){ref-type="fig"}A).In D283 Med cells, the expressions of 37 genes were changed (Figure [1](#F1){ref-type="fig"}B). Of these, 22 showed changes after combined treatment with ATRA and CA as well as with ATRA and CX. Changes in the expression of another 11 genes were identified after treatment with ATRA and CA only. Similarly, the expressions of 4 different genes were changed after treatment with ATRA and CX only (Figure [1](#F1){ref-type="fig"}B).The data achieved via expression profiling are presented after cluster analysis, which grouped the genes or gene groups by the type of changes in their expressions (Figure [2](#F2){ref-type="fig"}). Based on this analysis, three typical patterns of changes in gene expression are described:

![**Summary of detected changes in the expression of 440 cancer-related genes after the combined treatment of the Daoy (A) and D283 Med (B) cell lines.** The black circles indicate the total number of genes with changed expression after combinations of ATRA with CA or CX. The green areas indicate the number of genes with changed expression after combined treatment with ATRA and CA only. Similarly, the violet areas indicate the number of genes with changed expression after combined treatment with ATRA and CA only. The gray overlays indicate the number of genes that demonstrated changed expressions after treatment with ATRA in both combinations; i.e., with CA as well as with CX.](1475-2867-14-51-1){#F1}

![**Results of gene cluster analysis after the expression profiling of treated cells.** The genes were clustered according to the type of changes in the expression in the respective cell line (Daoy or D283 Med) after the combined treatment with ATRA and inhibitors (CA or CX). The cells were treated with ATRA alone or in combination with CA (an inhibitor of 5-LOX) or CX (an inhibitor of COX-2); numbers indicate the concentration in μM. The green color at the farthest left end of the color scale corresponds to the minimal value; the red color at the farthest right end of the color scale corresponds to the maximal value; the black color in the middle corresponds to the average value. Each of the other values corresponds to a certain color according to its magnitude. The colors are assigned according to the value of the particular gene expression in all samples in the respective experimental variant (I, II, III or IV). Genes discussed in the text in detail are highlighted by red dots.](1475-2867-14-51-2){#F2}

(i.) Genes with strong concentration-dependent changes in their expressions. This pattern was typical in the I.A, II.A, III.A, and IV.A groups, in which the upregulation of gene expression was detected. This concentration-dependent pattern was also detected in the groups with downregulated gene expressions, i.e., in the I.E., II.D, III.D, and IV.C groups.

(ii.) Genes for which the expression was upregulated (groups I.B and II.C) or downregulated (group III.C) after treatment with lower concentrations of reagents. The use of higher concentrations had no or minimal influence on the expression of these genes.

(iii.) Genes with changes in their expressions after treatment with higher concentrations of reagents only. This pattern was characteristic in the II.B and III.B groups; however, such trends were also obvious in the I.A and IV.A groups.

Similarities in the gene expression changes are summarized in Table [2](#T2){ref-type="table"} and Table [3](#T3){ref-type="table"}. The genes with changed expression in a particular cell line after combined treatment with ATRA and both inhibitors (CA or CX) are given: 8 genes were upregulated and 8 genes were downregulated in the Daoy cells; 16 genes were upregulated and 3 were downregulated in the D283 Med cells (Table [2](#T2){ref-type="table"}). Two of these genes, *GDF15* and *UBE2L6*, were upregulated in both cell lines after all types of combined treatment (Table [2](#T2){ref-type="table"}). Changes in gene expression after the same type of combined treatment (ATRA with CA or ATRA with CX) were identified in both cell lines; 2 of the genes were upregulated and 1 was downregulated after treatment with ATRA and CA, while 8 were upregulated and 1 was downregulated after treatment with ATRA and CX (Table [3](#T3){ref-type="table"}).

###### 

Genes with changed expression in a particular cell line (Daoy or D283 Med) after combined treatment with ATRA and both inhibitors (CA or CX)

  **Daoy cell line**        
  ------------------------ ------------------------------------------------------------------------------------------------------------------------------------------
  Upregulated:             *ACP2,****GDF15****, HLA-G, KRT18, MARS, NOTCH2, PPARG,****UBE2L6***
  Downregulated:           *CD24, COL6A3, FBN1, GAS6, HMGB1, JUND, PLK2, YBX1*
  **D283 Med cell line**    
  Upregulated:             *AP2M1, ATF4, BLMH, CANX, CDKN1A, COX6C, COX7A2, FTL,****GDF15****, MAP2K2, PFDN5, PPARD, RARA, RHOA, SOD1, TIMP1,****UBE2L6****, UCHL1*
  Downregulated:           *KPNA2, MYBL2, MYC*

The genes that were influenced via the combinations of both inhibitors are typed in bold.

###### 

Genes with changed expression detected after the same type of combined treatment (ATRA with CA or ATRA with CX) in both cell lines (Daoy and D283 Med)

  **ATRA/CA**       
  ---------------- -----------------------------------------------------------------------
  Upregulated:     ***GDF15, UBE2L6***
  Downregulated:   *CCND2*
  **ATRA/CX**       
  Upregulated:     *ATF4, CDKN1A,****GDF15****, HMGA1, HMGB1, PFDN5, TIMP1,****UBE2L6***
  Downregulated:   *AP2M1*

The genes that were influenced via the combinations of both inhibitors are typed in bold.

The analysis of the detected changes in gene expressions showed a concentration-dependent increase in the expression of genes known to be involved in the process of retinoid-induced differentiation and especially of the genes generally associated with the regulation of the cell cycle, of genes involved in mitochondrial metabolism, etc. The observed changes in the expressions of two selected candidate genes - *GDF15* (Figure [3](#F3){ref-type="fig"}) and *CDKN1A* (Figure [4](#F4){ref-type="fig"}) - were subsequently verified via RT-PCR.

![**Changes in the expression of the*GDF15*gene in Daoy (A) and D283 Med (B) cells analyzed using RT-PCR.** The cells were treated with ATRA alone or in combination with CA (an inhibitor of 5-LOX) or CX (an inhibitor of COX-2); numbers indicate the concentrations of these compounds in μM. Respective numerical data from densitometry for three independent experiments are shown in the graphs: X-axis, treatment condition; Y-axis, relative gene expression. The data represent the means ± SD; they were normalized to the expression of the *HSP90AB1* housekeeping gene and were related to the untreated control cells. Representative electrophoresis is presented for each cell line.](1475-2867-14-51-3){#F3}

![**Changes in the expression of the*CDKN1A*gene in Daoy (A) and D283 Med (B) cells analyzed using RT-PCR.** The cells were treated with ATRA alone or in combination with CA (an inhibitor of 5-LOX) or CX (an inhibitor of COX-2); numbers indicate the concentrations of these compounds in μM. Respective numerical data from densitometry for three independent experiments are shown in the graphs: X-axis, treatment condition; Y-axis, relative gene expression. The data represent the means ± SD; they were normalized to the expression of the *HSP90AB1* housekeeping gene and were related to the untreated control cells. Representative electrophoresis is presented for each cell line.](1475-2867-14-51-4){#F4}

Discussion
==========

At present, retinoids (powerful inducers of cell differentiation) have become a part of many therapeutic regimens in pediatric oncology, especially in the treatment of solid tumors of neurogenic origin \[[@B39]-[@B43]\]. In our previous experiments, we demonstrated the enhancement of the ATRA-induced differentiation of neuroblastoma cells via the combined application of LOX/COX inhibitors \[[@B20],[@B29]\].

In our present study, we profiled the expression of 440 cancer-related genes in medulloblastoma cells after the same type of combined treatment (see above). Our results clearly confirmed our previous finding that ATRA-induced cell differentiation is enhanced via combined treatment with CA (inhibitor of 5-LOX) or with CX (inhibitor of COX-2) because the expression of the genes involved in the process of induced differentiation is increased in a concentration-dependent manner. A comparison of two established medulloblastoma cell lines showed a higher sensitivity in Daoy cells (compared with D283 Med cells) to the combined treatment with ATRA and inhibitors; nevertheless, our pilot experiments indicated that D283 Med cells were apparently more sensitive to the ATRA alone \[[@B34],[@B44]\]. The same difference in sensitivity of Daoy and D283 Med cell lines to the ATRA was already described and the higher sensitivity of D283 Med cells is explained by expression of OTX2, a transcription factor, which was reported as a suppressor of neuronal differentiation in medulloblastoma cells \[[@B45]\].

The three patterns of changes in gene expression described here were very similar to our previous results on neuroblastoma cells \[[@B20]\]. In terms of the individual genes, we noted significant changes in the expression of the *GDF15*, *RHOA*, and *RHOC* genes. Although the expression of the *GDF15* gene was enhanced in both cell lines via combined treatment with ATRA and both inhibitors (Figures [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}), changes in the expression of the *RHOA* and *RHOC* genes were detected in the D283 Med cells only (Figure [2](#F2){ref-type="fig"}). These two genes are members of the Rho GTPases family and are known to participate in cytoskeleton rearrangement and regulation processes such as changes in cell morphology during cell differentiation, proliferation and motility \[[@B46],[@B47]\]. This finding is in accordance with our pilot study in which the decrease in proliferation activity and in the formation of multicellular aggregates was reported after the combined treatment (using CA or CX) of D283 Med cells \[[@B44]\].

The protein encoded by the *GDF15* gene is an important regulator of cell differentiation during embryonal development, especially in neural tissues \[[@B48]\]. This protein also has other important functions in the regulation of immune response or response to stress factors \[[@B49]\], and some studies have described its role as a paracrine mediator in the p53 cell signaling pathway that can inhibit cell proliferation and induce apoptosis \[[@B50],[@B51]\]. Furthermore, the expression of *GDF15* correlated with the amount of the p21 protein that was encoded by the *CDKN1A* gene \[[@B50],[@B51]\]. Although the overexpression of *GDF15* was detected in both cell lines after combined treatment with both inhibitors (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}), we observed some differences between these cell lines. The expression of *GDF15* increased in Daoy cells in a concentration-dependent manner (Figures [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}A), but the changes in *GDF15* expression in D283 Med cells were not so obvious (Figures [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}B).

As mentioned above, some previous studies have demonstrated a correlation between the expressions of the *GDF15* and *CDKN1A* genes \[[@B50],[@B51]\]. The *CDKN1A* gene encodes the p21 protein, which serves as an important regulator of the cell cycle progression via the inhibition of cyclin-dependent kinases. In our experiments, the expression of *CDKN1A* was enhanced in both cell lines after combined treatment with ATRA and CX, whereas the combination of ATRA and CA did not show a similar effect (Table [3](#T3){ref-type="table"}, Figure [4](#F4){ref-type="fig"}). The increase in *CDKN1A* expression after treatment with retinoids was described in many human malignancies under *in vivo* and *in vitro* conditions: acute promyelocytic leukemia \[[@B52]\], acute T-lymphoblastic leukemia \[[@B53]\], pre-B lymphoma \[[@B54]\], hepatoblastoma \[[@B55],[@B56]\], and neuroblastoma \[[@B57]-[@B60]\]. Our *in vitro* data confirmed these findings (especially in D283 Med cells) and also clearly showed that this effect of ATRA can be enhanced through its combined administration with CX (Figure [4](#F4){ref-type="fig"}B).

Furthermore, we detected the upregulated expression of the *UBE2L6* gene, which encodes a member of the E2 ubiquitin-conjugating enzyme family in both cell lines after combined treatment with both inhibitors (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). The overexpression of the *ACP2* gene encoding a beta-subunit of lysosomal acid phosphatase was observed in Daoy cells after combined treatment with both inhibitors (Table [2](#T2){ref-type="table"}). The upregulated expression of both of these genes indicated an increased activity of proteasome in the treated cells. Higher proteasome activity was reported in breast carcinoma cells \[[@B61]\] as well as in acute promyelocytic leukemia cells \[[@B62],[@B63]\] after treatment with retinoids. However, the relationship between retinoids and proteasome activity should be associated with resistance to retinoids \[[@B64]\]. This mechanism of resistance to retinoids, i.e., the increased activity of proteasome in Daoy cells, could be one of the possible explanations for the differing sensitivity demonstrated by these cell lines to ATRA treatment, as reported in our pilot study \[[@B44]\]. This hypothesis is also supported by the fact that the upregulation of the *UCHL1* gene encoding a deubiquitinating enzyme was detected in more sensitive D283 Med cells after combined treatment with both inhibitors (Table [2](#T2){ref-type="table"}). Moreover, the protein encoded by this gene was found solely in mature neurons \[[@B65]\]; its increased expression in D283 Med, which is apparently enhanced via a combined treatment with ATRA and inhibitors, should indicate the neuronal differentiation of D283 Med after experimental treatment.

Higher sensitivity of D283 Med cells to the ATRA-induced neuronal differentiation is also indicated by the overexpression of two genes encoding subunits of cytochrome C oxidase, *COX6C* and *COX7A2*, after both types of combined treatment (Table [2](#T2){ref-type="table"}). An increased mitochondrial activity after treatment with retinoids was reported in neuroblastoma cell lines \[[@B66]\], and it was demonstrated that more differentiated neuronal cells exhibit higher oxygen consumption rates as well as metabolic rates \[[@B67]\]. These findings thus support the presumed neuronal differentiation of D283 Med cells treated with ATRA and the capability of CA and CX to enhance this effect. Furthermore, a similar upregulation of these two genes was previously detected in neuroblastoma cell lines after the same type of experimental treatment \[[@B20]\].

The presented results are closely connected to our previously published studies reporting encouraging treatment responses to metronomic therapy in children suffering from some types of relapsed solid tumors with poor prognosis \[[@B42],[@B43],[@B68]\]. In these protocols, retinoids are administered in combination with celecoxib (as an anti-angiogenic agent) and several cytotoxic agents. The usefulness of this type of metronomic therapy was also demonstrated in patients with MBL \[[@B43],[@B69],[@B70]\]. In light of this, our experimental data clearly demonstrated that the combined administration of retinoids and celecoxib should also be beneficial in enhancing tumor cell differentiation. Furthermore, a very similar effect could be achieved through the dietary uptake of plant phenolic compounds including caffeic acid \[[@B71],[@B72]\].

Conclusion
==========

To summarize, our results on two established medulloblastoma cell lines -- Daoy and D283 Med -- confirmed our previous findings in leukemia and neuroblastoma cells that the differentiating effects of ATRA should be enhanced in its combined administration with caffeic acid (an inhibitor of 5-LOX) or celecoxib (an inhibitor of COX-2). This effect was apparently achieved in both cell lines via the increased expression of genes encoding proteins participating in inducing the differentiation and cytoskeleton remodeling (GDF-15, Rho GTPases) or the p21 protein, which is an important regulator of the cell cycle and of proteins associated with proteasome activity. Furthermore, our results showed an important difference between the established MBL cell lines: the Daoy cells showed the same sensitivity as the cell lines that were derived from other types of pediatric solid tumors, but the D283 Med cells were significantly more sensitive to the treatment with ATRA alone (this effect was further enhanced via combined treatment with LOX/COX inhibitors). To clarify detailed mechanisms of such difference, additional experiments concerning more cell lines derived from various MBL subtypes are needed. Nevertheless, the obtained results confirmed our initial hypothesis regarding the common mechanism of enhancement in ATRA-induced cell differentiation in various types of pediatric solid tumors.
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